Scarica l'app Stockscreener
2.79
3.79%
-0.11
Dopo l'orario di chiusura:
2.80
0.010
+0.36%
Precedente Chiudi:
$2.90
Aprire:
$2.9
Volume 24 ore:
111.51K
Relative Volume:
0.46
Capitalizzazione di mercato:
$77.78M
Reddito:
-
Utile/perdita netta:
$-14.14M
Rapporto P/E:
-3.0326
EPS:
-0.92
Flusso di cassa netto:
$-12.64M
1 W Prestazione:
-4.45%
1M Prestazione:
+24.55%
6M Prestazione:
+36.10%
1 anno Prestazione:
+35.44%
Intervallo 1D:
$2.74
$2.90
Intervallo di 1 settimana:
$2.74
$3.0993
Portata 52W:
$1.26
$3.12
Immix Biopharma Inc Stock (IMMX) Company Profile
Nome
Immix Biopharma Inc
Settore
Industria
Telefono
(888) 958-1084
Indirizzo
11400 WEST OLYMPIC BLVD., LOS ANGELES
Confronta IMMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.79 | 79.45M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Immix Biopharma Inc Borsa (IMMX) Ultime notizie
Is Immix Biopharma Inc. stock a growth or value playFree Predictions - jammulinksnews.com
What analysts say about Immix Biopharma Inc. stockFree Stock Market Knowledge Sharing - Autocar Professional
Is Immix Biopharma Inc. a good long term investmentRecord-setting profit potential - jammulinksnews.com
Immix Biopharma Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com
What drives Immix Biopharma Inc. stock priceTremendous wealth creation - jammulinksnews.com
What makes Immix Biopharma Inc. stock price move sharplyFree AI-Powered Stock Predictions - Newser
Why Immix Biopharma Inc. stock attracts strong analyst attentionHigh Yield Opportunities - Newser
How Immix Biopharma Inc. stock performs during market volatilityBreakout Level Watch - Newser
ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis - Investing.com Nigeria
ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis By Investing.com - Investing.com South Africa
Immix Biopharma Says NXC-201 Safety Profile Shows Absence of Neurotoxicity in Low-Volume Disease - MarketScreener
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - MarketScreener
Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission - Nasdaq
Revolutionary CAR-T Safety Data: IMMX Reports Zero Neurotoxicity in Rare Disease Treatment - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% – Here’s Why - Defense World
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Immix Biopharma Expands NEXICART-2 Trial Sites Nationwide, Progressing Towards Biologics License Application for Cell Therapy in AL Amyloidosis - Nasdaq
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - GlobeNewswire
Breakthrough Cell Therapy for AL Amyloidosis Accelerates Toward FDA Approval with 18 Trial Sites - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Upgraded by Wall Street Zen to Hold Rating - Defense World
Immix Biopharma Holds Annual Meeting, Elects Directors - TipRanks
Immix Biopharma CEO Rachman buys $4998 in shares - Investing.com
Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World
Immix Biopharma Inc Azioni (IMMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):